Last reviewed · How we verify
Conversion to Once-daily Tacrolimus
At a glance
| Generic name | Conversion to Once-daily Tacrolimus |
|---|---|
| Also known as | TacroBell slow-release cap. |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients (PHASE4)
- CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients (PHASE2, PHASE3)
- Envarsus Neurotoxicity Burden in Liver Transplant Patients (PHASE4)
- Liver Transplantation With Tregs at MGH (PHASE1, PHASE2)
- Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients (PHASE4)
- A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)
- Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients (PHASE4)
- A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: